Michael Szarek, PhD, on the Next Steps for Tivozanib in Patients with Advanced RCC

Video

An analysis revealed that as a third- or fourth-line treatment for advanced renal cell carcinoma, tivozanib significantly increased Q-TWiST compared with sorafenib, primarily through an increase in TWiST.

Results of an analysis of tivozanib (Fotivda) versus sorafenib (Nexavar) in patients with advanced renal cell carcinoma (RCC) included in the phase 3 TIVO-3 study (NCT02627963) suggest Q-TWiST may be considered an alternative patient-centered measure of benefit in these settings.

The analysis, presented at the American Society of Clinical Oncology (ASCO) 2021 Genitourinary Cancers Symposium, revealed that as a third- or fourth-line treatment for RCC, tivozanib significantly increased Q-TWiST compared with sorafenib, primarily through an increase in TWiST.

In an interview with CancerNetwork®, Michael Szarek, PhD, of the SUNY Downstate Medical Center, spoke about the next steps for tivozanib in this patient population.

Transcript:

First, we’re looking to publish more details on this particular analysis; we’re looking to publish the manuscript about it. The drug itself is approved in Europe, but it’s not yet approved in the United States; however, the [new drug application] is under review currently. This drug has been studied in front-line renal cell cancer and in later-line [settings]. The sponsor, who is Aveo, is hoping that these TIVO-3 trial results will support its approval. From my understanding, it’s currently under review. The results of that review are pending.

Reference:

Szarek M, Needle MN, Rini BI, et al. Q-TWiST analysis of tivozanib (T) versus sorafenib (S) in patients with advanced renal cell carcinoma (RCC) in the TIVO-3 study. J Clin Oncol. 2021;39(suppl 6):298. doi: 10.1200/JCO.2021.39.6_suppl.298

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content